<DOC>
	<DOCNO>NCT00773929</DOCNO>
	<brief_summary>The purpose study determine safety toxicity profile TAK-593 determine maximum tolerate dose TAK-593 .</brief_summary>
	<brief_title>Safety Study TAK-593 Given Orally Subjects With Nonhematologic Advanced Cancer</brief_title>
	<detailed_description />
	<criteria>â‰¥ 18 year age diagnose advanced solid tumor cancer fail respond standard therapy treatment option available . No prior chemotherapy Able understand follow study requirement Subject subject 's legal representative sign write , informed consent form prior begin study procedure . Women postmenopausal least 1 year screen surgically sterile Women childbearing potential agree practice two effective method birth control time sign informed consent form 30 day last dose study drug agree completely abstain heterosexual intercourse . Men agree practice effective method birth control entire study treatment period 30 day last dose study drug completely agree abstain heterosexual intercourse . Ability swallow retain oral medication Meet study specific laboratory test standard bone marrow function , liver function , blood pressure , renal function . Cancer spread brain History another cancer diagnose treat within past 3 year . Severe cardiovascular issue include heart attack within past 6 month , unstable angina arrhythmia require treatment . Severe thyroid disease Unstable angina Arrhythmia issue History bleed issue Serious wound , ulcer bone fracture heal Subject pregnant breast feeding Subject illness condition may affect ability participate study Subject participate another clinical study/post marketing clinical study within 4 week prior start trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
</DOC>